U.S. researchers said Wednesday they have reproduced the pain-relieving effects of cannabis with a synthesized compound that ...
In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated ...
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
Vertex’s new drug Journavx (suzetrigine) has been hailed as a scientific breakthrough because it allays pain without entering the brain, minimizing the risk of addiction and dependence that can ...
The FDA approved Journavx on Thursday following a pair of clinical trials on 874 participants with moderate to severe acute pain following abdominoplasty — commonly known as a "tummy tuck ...
But for some, the claims by Vertex Pharmaceuticals that Journavx is not habit-forming, unlike opioid painkillers, leaves them a bit skeptical — it’s something they’ve heard before ...
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain that often follows surgery or injuries. It’s the first new pharmaceutical approach to ...
The United States Food and Drug Administration (FDA) has approved a new non-opioid prescription medication, Journavx (suzetrigine), for adults with moderate to severe acute pain. Developed by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback